The BT Longevity & Health Research Center is a high-tech biotech enterprise invested by the Group. It holds the world’s largest collection of “ginsenoside” reference standards and proprietary patented technologies, focusing on deep R&D and industrialization of 150-year-old ginseng cultured root cell technology.

Groundbreaking work begins with 150-year-old natural wild ginseng root tissue, establishing a specialized culture system through precise isolation, callus induction, and cell line screening. Its proprietary patented enzyme conversion technology (ECS) precisely converts more than 20 nearly non-absorbable ginsenosides (such as Rg1 and Rb1) into easily absorbable rare ginsenosides (such as Compound-K and Rg3), boosting the average human absorption rate from 50% to over 95%. This enables 150-year-old ginseng cultured root cells to successfully cross the technical barrier from laboratory gram-scale production to industrial ton-scale manufacturing.

Looking ahead, BT will continue to advance its scientific, premium, and global strategies, leading end-to-end innovation from source cell culture to end-product application, and contributing to a healthier future with cutting-edge biotechnology.